Unpacking the R&D Tax Incentive for the Australian LifeSciences sector

Australia’s R&D Tax Incentive is one of the most significant programs driving investment and innovation in the life sciences. But how does it really work in practice, and what do the latest transparency data tell us about the companies claiming it?In this episode of the ARCS Cognitio Podcast, host Tim Boyle brings you highlights from a recent ARCS webinar with experts from EY. Together they unpack:The first tranche of R&D Tax transparency data and what it means for biotech, medtech, and clinical research.How companies can structure their claims and avoid common pitfalls.Key differences between Australian-owned and foreign-owned R&D arrangements.What regulators are focusing on in their compliance reviews.Whether you’re part of a multinational pharma, a startup biotech, or a contract research organisation, this episode provides practical insights into maximising the benefit of the R&D Tax Incentive while staying compliant.Listen now to understand how the program can support your organisation—and where the risks lie.

There are no comments yet.

Please log in to write the first comment.